Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer
about
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupOzone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients.Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer.Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions.Defining a dose-response relationship for prostate external beam radiotherapy.Canadian prostate brachytherapy in 2012.Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position.Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.A new dawn in prostate cancer management: Do we have the trials to support it?Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy.
P2860
Q27011661-24A53A0B-3A0B-410C-853C-D887ED28EF09Q33466062-CD6C6B3A-1B68-4B8B-A8E9-EA0DF3D6DF8BQ34795596-F98A06BF-64CC-49D3-95E1-DE23E3EF7432Q35079338-301AD171-9E1D-4C85-BC08-931C20EBF501Q36276830-A9486B32-E9C9-4981-84CC-C096A6E6D46FQ37512971-9BB83E9C-CD88-4F41-8DC1-7E8B9FB90B27Q37965553-185BA643-C01D-4226-A78C-9B6DEDF93DCDQ38095668-1C4EAF07-EA0C-4727-B8D7-B55C4C935921Q38106699-370DD33E-ED58-4991-BB48-912B716239FBQ41541990-5FF38A3E-A4C7-4628-BDE9-60787D85585AQ41787712-8BAC1A2F-829C-462B-A02C-628D74F92EC3Q41925779-964B64CF-379C-49A1-9CDB-E4F9FD271D97Q41952611-7C6E7D43-4F42-4212-BFC6-194E336B29D9Q42755577-456D5A6D-BB63-4215-870F-AEBBF211F877Q42948018-13CC0CF0-64A3-47E1-9D19-7E7C3304A685
P2860
Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of tumor control an ...... favorable risk prostate cancer
@ast
Comparison of tumor control an ...... favorable risk prostate cancer
@en
type
label
Comparison of tumor control an ...... favorable risk prostate cancer
@ast
Comparison of tumor control an ...... favorable risk prostate cancer
@en
prefLabel
Comparison of tumor control an ...... favorable risk prostate cancer
@ast
Comparison of tumor control an ...... favorable risk prostate cancer
@en
P2093
P2860
P1433
P1476
Comparison of tumor control an ...... favorable risk prostate cancer
@en
P2093
Gilad Cohen
Marco Zaider
Margie Hunt
Michael J Zelefsky
Yoshiya Yamada
Zhigang Zhang
P2860
P304
P356
10.1016/J.UROLOGY.2010.07.539
P407
P577
2010-12-31T00:00:00Z